ArticleStem cells and development2013
Commercialization and stem cell research: a review of emerging issues.
Article in Stem cells and development, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Better governance starts with better words: why responsible human tissue research demands a change of language.BMC medical ethics · 2022Article
- Stem cell translational medicine: The Tianjin model revisited.Stem cells translational medicine · 2021Article
- Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials.Stem cell research & therapy · 2018Review
- Attitude of A Sample of Iranian Researchers toward The Future of Stem Cell Research.Cell journal · 2018Article
- Consent for governance in the ethical use of organoids.Nature cell biology · 2018Article
- Biological Therapies in Regenerative Sports Medicine.Sports medicine (Auckland, N.Z.) · 2017Review
- Umbilical cord blood banking: from personal donation to international public registries to global bioeconomy.Journal of blood medicine · 2014Review
- Repurposing research data for commercial use: POPIA, a foil or a facilitator?South African journal of scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell researchers face pressure to develop therapies that will reach the clinic within a short period of time. Yet, this pressure may be unrealistic, as bringing stem cell innovations to the clinic will likely require significant time and financial investment. In a variety of biomedical fields, some evidence suggests that commercialization pressures and strategies may negatively impact research. These negative impacts may also be felt in the field of stem cell research, unless the challenges and issues are addressed in the design and implementation of commercialization policies. Further inquiry into the impact of commercialization on the field of stem cell research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.